Highly Specific Blood Test Detects Creutzfeldt-Jakob Disease
|
By LabMedica International staff writers Posted on 20 Mar 2014 |
|
Image: Spongiform change in vCJD (Photo courtesy of Wikimedia Commons).
A preliminary study has indicated that a blood test for infection by the prion that causes variant Creutzfeldt-Jakob disease (vCJD) has sufficient sensitivity and specificity to justify a large study comparing vCJD prevalence in the United Kingdom with a bovine spongiform encephalopathy-unexposed population.
vCJD is a fatal degenerative brain disorder thought to be caused by a misfolded protein (prion) in the brain and contracted most commonly through eating beef infected with BSE (bovine spongiform encephalopathy). Up to three million cattle in the United Kingdom may have been infected with BSE, and establishing accurate prevalence estimates through screening for vCJD infection would guide public health initiatives.
Investigators at University College of London (United Kingdom) employed a prototype test (now in clinical diagnostic use) that captured, enriched, and detected disease-associated prion protein from whole blood samples using stainless steel powder to determine the presence of vCJD infection in 5,000 blood samples from US donors, 200 samples from healthy United Kingdom donors, 352 samples from patients with non-prion neurodegenerative disease, 105 samples from patients in whom a prion disease diagnosis was likely, and 10 samples from patients with confirmed vCJD.
Results revealed that the assay’s specificity among the presumed negative American donor samples was 100%, which was confirmed in the healthy United Kingdom cohort (100% specificity). Of potentially cross-reactive blood samples from patients with non-prion neurodegenerative diseases, no samples tested positive. The test identified as positive 71.4% of the patients with vCJD.
The authors concluded that, "Most importantly, the prototype vCJD assay has sufficient performance to justify now screening a large United Kingdom population sample and at-risk groups to produce an initial estimate of the level of prionemia [prions in the blood] in the United Kingdom blood donor population. A blood prevalence study would provide essential information for policy makers for deciding if routine vCJD screening is needed for blood, tissue, and organ donations and patients prior to high-risk surgical procedures."
The study was published in the March 3, 2014, online edition of the Journal of the American Medical Association Neurology (JAMA Neurology).
Related Links:
University College of London
vCJD is a fatal degenerative brain disorder thought to be caused by a misfolded protein (prion) in the brain and contracted most commonly through eating beef infected with BSE (bovine spongiform encephalopathy). Up to three million cattle in the United Kingdom may have been infected with BSE, and establishing accurate prevalence estimates through screening for vCJD infection would guide public health initiatives.
Investigators at University College of London (United Kingdom) employed a prototype test (now in clinical diagnostic use) that captured, enriched, and detected disease-associated prion protein from whole blood samples using stainless steel powder to determine the presence of vCJD infection in 5,000 blood samples from US donors, 200 samples from healthy United Kingdom donors, 352 samples from patients with non-prion neurodegenerative disease, 105 samples from patients in whom a prion disease diagnosis was likely, and 10 samples from patients with confirmed vCJD.
Results revealed that the assay’s specificity among the presumed negative American donor samples was 100%, which was confirmed in the healthy United Kingdom cohort (100% specificity). Of potentially cross-reactive blood samples from patients with non-prion neurodegenerative diseases, no samples tested positive. The test identified as positive 71.4% of the patients with vCJD.
The authors concluded that, "Most importantly, the prototype vCJD assay has sufficient performance to justify now screening a large United Kingdom population sample and at-risk groups to produce an initial estimate of the level of prionemia [prions in the blood] in the United Kingdom blood donor population. A blood prevalence study would provide essential information for policy makers for deciding if routine vCJD screening is needed for blood, tissue, and organ donations and patients prior to high-risk surgical procedures."
The study was published in the March 3, 2014, online edition of the Journal of the American Medical Association Neurology (JAMA Neurology).
Related Links:
University College of London
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Ultrasonic Cleaner
UC 300 Series
Latest Pathology News
- AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
- AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
- AI-Based Model Predicts Kidney Cancer Therapy Response
- Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
- World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
- Breakthrough Diagnostic Approach to Significantly Improve TB Detection
- Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
Molecular Diagnostics
view channel
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
